Tecentriq_SCLC(1L)_Bev_comb[BEAT-SC]
- Conditions
- Extensive-stage Small Cell Lung Cancer
- Registration Number
- JPRN-jRCT2080224946
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 330
Histologically or cytologically confirmed ES-SCLC
- No prior treatment for ES-SCLC
- ECOG performance status of 0 or 1
- Measurable disease, as defined by RECIST v1.1
- Adequate hematologic and end organ function
- Malignancies other than SCLC within the last 5 years
- Pregnant or lactating women
- History of autoimmune disease
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
- Positive test for Human Immunodeficiency Virus (HIV)
- Active hepatitis B or hepatitis C
- Severe infections at the time of enrollment
- Significant cardiovascular disease
- Prior treatment with immune checkpoint blockade therapies, anti-PD1 and anti-PD-L1 therapeutic antibody
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method